Literature DB >> 27854559

The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome.

Kimberly A Yonkers1,2,3, Brianna Cameron4, Ralitza Gueorguieva4, Margaret Altemus5, Susan G Kornstein6.   

Abstract

BACKGROUND: Some women who use cyclic hormonal contraception (CHC) suffer from premenstrual symptoms; whether their symptoms differ from women who do not use CHC is not clear.
OBJECTIVE: To compare women who use or do not use CHC on perimenstrual symptom timing and change severity. STUDY
DESIGN: We analyzed daily symptom ratings from women who requested participation in (Screened Cohort: 103 used CHC and 387 did not) or were randomized in (Randomized Cohort: 41 used CHC and 211 did not) a clinical trial for premenstrual syndrome. We used effect sizes to compute and compare change scores between cycle phases in four partially overlapping perimenstrual windows defined relative to day 1 of menses [(-6, -1), (-5, 1), (-4, 2), (-3, 3)]. Differences in magnitude of change and timing were estimated using linear mixed-effects models.
RESULTS: Both cohorts showed a significant two-way interaction between CHC use and symptom change scores (p < 0.01) and a significant main effect of perimenstrual window (p < 0.0001). Overall menstrual cycle symptom change was greater for the nonhormonal contraception versus hormonal contraception group. In the Screened Cohort, change scores were greater in the nonhormonal group specifically for depression (p = 0.04); anger or irritability (p < 0.01); and physical symptoms (p < 0.01). Mean change scores increased as the window shifted forward toward menses for both cohorts with the largest effect size and greatest group difference for (-4, 2) interval.
CONCLUSIONS: CHC slightly attenuates menstrual cycle symptom change. The (-4, 2) perimenstrual interval shows the largest change compared with postmenses.

Entities:  

Keywords:  contraception; menstrual cycle; mental health

Mesh:

Substances:

Year:  2016        PMID: 27854559      PMCID: PMC5397197          DOI: 10.1089/jwh.2016.5941

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  22 in total

1.  Daily self-reports on activities, life events, moods, and somatic changes during the menstrual cycle.

Authors:  L A Wilcoxon; S L Schrader; C W Sherif
Journal:  Psychosom Med       Date:  1976 Nov-Dec       Impact factor: 4.312

2.  Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.

Authors:  E W Freeman
Journal:  Eur J Contracept Reprod Health Care       Date:  2002-12       Impact factor: 1.848

Review 3.  Factor structure of the modified Moos Menstrual Distress Questionnaire: assessment of prospectively reported follicular, menstrual and premenstrual symptomatology.

Authors:  C Ross; G Coleman; C Stojanovska
Journal:  J Psychosom Obstet Gynaecol       Date:  2003-09       Impact factor: 2.949

4.  Menstrual cycle symptom variation in a community sample of women using and not using oral contraceptives.

Authors:  H Sveinsdóttir; T Bäckström
Journal:  Acta Obstet Gynecol Scand       Date:  2000-09       Impact factor: 3.636

5.  An assessment of psychological state associated with the menstrual cycle in users of oral contraception.

Authors:  A Marriott; E B Faragher
Journal:  J Psychosom Res       Date:  1986       Impact factor: 3.006

6.  Mood, sexuality, oral contraceptives and the menstrual cycle.

Authors:  P Warner; J Bancroft
Journal:  J Psychosom Res       Date:  1988       Impact factor: 3.006

7.  Effects of oral contraceptives on affective fluctuations associated with the menstrual cycle.

Authors:  K E Paige
Journal:  Psychosom Med       Date:  1971 Nov-Dec       Impact factor: 4.312

8.  Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets.

Authors:  S Ann Hartlage; Sally Freels; Nathan Gotman; Kimberly Yonkers
Journal:  Arch Gen Psychiatry       Date:  2012-03

Review 9.  Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus.

Authors:  Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen Freeman; Uriel Halbreich; Khaled M K Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; Peter Schmidt; Meir Steiner; John Studd; Kimberley Yonkers
Journal:  Arch Womens Ment Health       Date:  2011-01-12       Impact factor: 3.633

10.  Oral contraception and cyclic changes in premenstrual and menstrual experiences.

Authors:  S Abraham; G Luscombe; I Soo
Journal:  J Psychosom Obstet Gynaecol       Date:  2003-09       Impact factor: 2.949

View more
  5 in total

Review 1.  Effects of Hormonal Contraceptives on Mood: A Focus on Emotion Recognition and Reactivity, Reward Processing, and Stress Response.

Authors:  Carolin A Lewis; Ann-Christin S Kimmig; Rachel G Zsido; Alexander Jank; Birgit Derntl; Julia Sacher
Journal:  Curr Psychiatry Rep       Date:  2019-11-07       Impact factor: 5.285

2.  Early- and Late-Luteal-Phase Estrogen and Progesterone Levels of Women with Premenstrual Dysphoric Disorder.

Authors:  Ju-Yu Yen; Huang-Chi Lin; Pai-Cheng Lin; Tai-Ling Liu; Cheng-Yu Long; Chih-Hung Ko
Journal:  Int J Environ Res Public Health       Date:  2019-11-07       Impact factor: 3.390

3.  Development of a Japanese Version of the Daily Record of Severity of Problems for Diagnosing Premenstrual Syndrome.

Authors:  Yumie Ikeda; Miho Egawa; Kazuko Hiyoshi; Tsukasa Ueno; Keita Ueda; Carl B Becker; Yoshimitsu Takahashi; Takeo Nakayama; Masaki Mandai
Journal:  Womens Health Rep (New Rochelle)       Date:  2020-01-20

4.  Views of Dutch general practitioners about premenstrual symptoms: A qualitative interview study.

Authors:  Marijke S Labots-Vogelesang; Doreth A M Teunissen; Vivianne Kranenburg; Antoine L M Lagro-Janssen
Journal:  Eur J Gen Pract       Date:  2021-12       Impact factor: 1.904

5.  Effect of Garlic (Allium sativum) Supplementation on Premenstrual Disorders: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Fatemeh Jafari; Malihe Tabarrai; Alireza Abbassian; Farhad Jafari; Mohammad Hossein Ayati
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-01       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.